Juergen Martens

This profile gathers the share dealings of Juergen Martens across 2 companies, led by Mannkind Corp and Neos Therapeutics, Inc. The record holds 116 filings, for trades running from 16 February 2006 to 1 May 2017.

In open-market terms, that means 7 purchases worth €276k on one side and 29 sales worth €5.8M on the other. Netting one side against the other leaves €5.5M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 65 share grants and 15 option exercises.

The median purchase comes to €25k. Looking at 6 purchases old enough to measure, the stock rose over the following 90 days in 17% of cases; the median change was -27.9%. This is a record of the past, not a forecast.

On 2 May 2017 came the latest disclosure, a share grant in Neos Therapeutics, Inc. The most recent open-market purchase was published on 14 June 2016, 3,799 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.